Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

Benzinga · 4d ago
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.